Skip to content
StockMarketAgent
Direct answer
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation. Fair value range: low $230, high $450, with mid-point at $340.
Stock analysis

UNH UnitedHealth Group Incorporated fair value $340–$450

UNH
By StockMarketAgent.AI team· supervised by
已分析: 2026-05-08下次更新: 2026-08-08Methodology v2.4Archetype: Mature compounderNYSE · Health Care
View archive
股价
$378.06
▼ -38.07 (-10.07%)
公允价值
$340
$340–$450
评级
减持
confidence 88/100
上行空间
-10.1%
upside to fair value
安全边际
$288.99
buy below · 15%
市值
$343.3B
P/E fwd 18.2
英文原文ZH
翻译期间显示英文原文
此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

§1 执行摘要

  • UNH offers unmatched scale in healthcare but currently faces acute near-term margin pressure.
  • Valuation models heavily cap aggressive extrapolations, yielding a grounded $339.99 fair value.
  • The current price of $378.07 embeds growth expectations that risk a multiple de-rating.
Fair value
$340
Margin of safety
-11.2%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$378.07Price
FV $339.99
High $449.63

UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.

  • Cycle upside
    Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.

§2 看空情景

A severe stress test assumes operating margins structurally compress to 4.2% without recovery, dragging ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. below WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. and stalling free cash flow generation indefinitely.

该论点可能失败的方式

Permanent MA Rate Cuts

· Medium

Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.

FV impact
Severe reduction to the low-end $230 fair value range.
Trigger
12-24 months

Runaway Medical Inflation

· Medium

Utilization rates remain permanently elevated while value-based care initiatives fail to offset the structural MCR deterioration.

FV impact
Midpoint collapses below $300 due to EPS and FCF stagnation.
Trigger
6-18 months

Antitrust Optum Breakup

· Low

Aggressive regulatory intervention forces the spin-off or severe operational firewalling of Optum from UnitedHealthcare.

FV impact
Sustained multiple compression and loss of integrated scale synergies.
Trigger
36-60 months
需关注的早期预警信号
指标当前触发阈值
Medical care ratio consistently exceeds the 84% threshold.MonitorDeterioration versus the report thesis
Optum Health revenue growth decelerates below 5% annually.MonitorDeterioration versus the report thesis
Operating margins fail to breach the 6% normalized assumption.MonitorDeterioration versus the report thesis
Regulatory changes successfully cap Medicare Advantage profitability.MonitorDeterioration versus the report thesis
Free cash flow conversion persistently drops below net income.MonitorDeterioration versus the report thesis

§3 财务历史

损益表 — 最近六期
项目T−0T−1T−2T−3T−4CAGR
期间2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
营业收入$287.60B$324.16B$371.62B$400.28B$447.57B+11.7%
毛利$69.65B$79.62B$90.96B$89.40B$82.92B+4.5%
营业利润$23.97B$28.44B$32.36B$32.29B$18.96B-5.7%
净利润$17.29B$20.12B$22.38B$14.41B$12.06B-8.6%
每股收益(摊薄)$18.08$21.18$23.86$15.51$13.23-7.5%
EBITDA$27.07B$31.84B$36.33B$28.08B$23.06B-3.9%
研发
销售管理费用

质量评分

Piotroski F 评分
6 / 9
0–9 质量综合
Altman Z 评分
2.97
破产风险 (>3 安全)
OCF / 净利润
1.63×
>1 表示盈利质量高
会计质量门槛
Pass
经行业调整门槛
ROIC
8.6%
投入资本回报率
第 3 节

Numbers analysis

个人订阅用户 — §4 及之后还有 11 个章节

阅读完整分析 — 还有 11 个章节。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

涵盖每个股票的完整报告
24 个月的评级存档
关注列表简报 + 评级变更提醒
以任意语言导出 PDF + DOCX
开始免费试用
可随时取消。
FAQ

UNH — frequently asked questions

  1. Based on our latest independent analysis, UNH screens modestly overvalued. The current price is $378 versus a composite fair-value midpoint of $340 (range $230–$450), which implies roughly 10.1% downside to the midpoint.
Related coverage

Names readers of UNH also follow

Same archetype: mature-compounder
Same sector: Health Care